

UltraBurst™

First-in-Class Flash ODT Platform for Direct Compression


Your team works hard to create a product that patients want to take. SPI Pharma has an extensive history of providing innovative, patient-centric oral dose excipients and solutions to our customers within the global pharma and nutraceutical industries. Combining our orally-dispersible technology expertise with our recent innovations in polyol and excipient development, we deliver a premium platform to improve orally-disintegrating tablet (ODT) performance and patient experience.

UltraBurst is the first-ever, co-processed excipient platform for flash ODTs, delivering revolutionary results with an evolutionary process. UltraBurst is designed for direct compression and is easy to formulate, resulting in tablets with ultra-fast disintegration, low friability, and excellent organoleptics.

Flash Disintegration

UltraBurst improves disintegration time for ODTs of all sizes. It opens the door to faster disintegration for traditionally difficult-to-formulate APIs and smaller ODT tablets with higher API loads. The production of robust, ultra-fast disintegrating tablets in standard packaging is now possible.

Made from compendial excipients, the UltraBurst flash ODT platform requires minimal additional ingredients and enables customers to produce direct compression, fast-disintegrating tablets using standard machinery.



Disintegration versus hardness compared to other commercially available ODT platforms.

UltraBurst provides flash ODT performance for low-dose APIs using standard direct compression. Additionally, UltraBurst improves disintegration time vs. competitive direct compression preformulations across various tablet weights and API loadings.



Tablet Robustness

Weight (mg)	Tablet Size FFBE mm	Compression Force (kN)	Thickness(mm)	Hardness (N)	Friability (%)	DT (sec)
50	6.2	0.5	1.6	15	0.3	3
100	7.0	1.4	2.4	30	0.1	5
150	8.7	2.1	2.4	29	0.1	6
200	9.5	3.0	2.7	30	0.2	9

UltraBurst produces tablets with exceedingly quick disintegration, best-in-class hardness, and low friability across a range of tablet sizes enabling standard packaging and avoiding bulky blister packs.

Content Uniformity

		Formula A mg/tab	Formula B mg/tab	Formula C mg/tab
Ingredient	UltraBurst	60	60	60
	DPH Resinate	38.5 (53µm)	38.5 (99µm)	38.5 (200µm)
	Magnesium stearate	1.5	1.5	1.5
	Total	100	100	100
Content Uniformity	Min	98.9	95.1	96.3
	Max	102.8	99.1	103.3
	Mean	100.9	97.5	99.6
	AV value (Limit 15)	2.9	4.3	5.5

To create maximum patient-centric value, ODTs often need to incorporate large, taste-masking APIs. UltraBurst rises to the challenge of incorporating a variety of API sizes while maintaining content uniformity.

Technical Support

UltraBurst opens doors that were previously closed to some formulators based on requirements like disintegration time or drug load (tablet size). If your team is unsure of where or how to start, SPI Pharma's customer-focused Technical Development Managers are here to help quickly and efficiently formulate your drug product.

Does your project require a bit more support due to aggressive timelines or technical demands? Our custom formulation services from our expert ODT formulators are available for a fee.

Request a sample and get started today.

 SPI Pharma

 salesinfo@spipharma.com

 @spipharma_real

 @spipharma

 www.spipharma.com

 SPI Pharma



All information and statements given in this brochure are believed to be accurate at the time of publication. However, neither SPI Pharma nor any of their affiliates make any representations or warranty with respect thereto, including, but not limit to, any results obtained in the processing of the products by customers or any third party. All information and statements are intended for persons having the required skill and know-how and do not relieve the customer or user from verifying the suitability of information and statements given for a specific purpose prior to use of products. It is entirely the obligation of the customer or user to comply with applicable laws and regulations, and with all patent or other intellectual property rights of third parties.

SPI PHARMA EXPRESSLY DISCLAIMS ANY REPRESENTATIONS OR WARRANTIES OF ANY KIND, WHETHER EXPRESS OR IMPLIED, AS TO THE ACCURACY, CURRENCY, COMPLETENESS AND/OR THE MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OF ANY INFORMATION CONTAINED IN THIS BROCHURE AND/OR ANY PRODUCT DESCRIBED OR PROMOTED IN THIS BROCHURE, INCLUDING WARRANTIES WITH RESPECT TO INFRINGEMENT OF ANY PATENT, COPYRIGHT, OR OTHER RIGHTS OF A THIRD PARTY. We reserve the right to change product specification and not specified properties of the products without prior notice.